牛唐2018-07-28 22:07
$Foamix(FOMX)$ FMX101是外用的minocyline,用于治疗痤疮,预计今年下半年或明年上半年申报NDA,如果获批的话,将是首个获批的米诺环素外用药查看全文
usbiostock2018-05-07 23:03
$Foamix(FOMX)$ FX201722临床3期试验已完成最后一名患者入组,该试验旨在评估FXM101(4%米诺环素)治疗痤疮的疗效和安全性。一线数据预计在2018年第三季度公布。查看全文
蚁竹052022-05-18 14:38
#“宝宝类”基金破2,闲钱放哪好?#@耐力投资 .....? @石木见 I I'm v $中科金财(SZ002657)$ I I'm @死磕新城一千天 $Foamix(FOMX)$ u up @娜一年查看全文
chuminhua2019-11-11 23:13
11/11,Menlo Therapeutics$Menlo Therapeutics(MNLO)$ 与以色列皮肤科生物技术公司Foamix$Foamix(FOMX)$ 达成合并交易,以防止更多失败。几周前,FDA批准了Foamix的痤疮药物,此外该公司还已经向FDA提交了米诺环素用于中度至重度丘疹脓疱型酒渣鼻。Menlo仅有一个在研产品serlopitant,但是一年前...查看全文
chuminhua2019-10-21 11:31
10/18,Foamix Pharmaceuticals$Foamix(FOMX)$ 公司宣布,美国FDA批准该公司的Amzeeq(minocycline,原名FMX101)上市,治疗非结节性中重度痤疮患者的炎症性病变(成年和9岁以上儿科患者)。Amzeeq是一种浓度为4%的米诺环素泡沫疗法,这是首款获得FDA批准的外用米诺环素疗法。网页链接查看全文
一年交易一次2018-11-08 18:00
$Foamix(FOMX)$ 计划于北京时间 2018-11-08 21:30(2018/11/08 08:30 EST)举行 2018 财年 Q3 财报电话会议。
Foamix于2003年1月19号在以色列成立。该公司是一家临床阶段制药公司专注于开发和商业化公司专有的泡沫米诺环素治疗痤疮,脓疱疮等皮肤状况。该公司的主导候选产品,fmx101为中度至重...查看全文
牛唐2018-07-28 22:07
$Foamix(FOMX)$ FMX101是外用的minocyline,用于治疗痤疮,预计今年下半年或明年上半年申报NDA,如果获批的话,将是首个获批的米诺环素外用药查看全文
$Foamix(FOMX)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-000600 Act: 33 Size: 1 KB 网页链接
$Foamix(FOMX)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001104659-20-035792 Act: 34 Size: 10 KB 网页链接
$Foamix(FOMX)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001104659-20-035405 Act: 33 Size: 38 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035407 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035409 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035410 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035413 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-019905 Size: 19 KB 网页链接
$Foamix(FOMX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001178913-20-000792 Act: 34 Size: 8 MB 网页链接
$Foamix(FOMX)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001178913-20-000788 Act: 34 Size: 296 KB 网页链接